Immunomodulation and immunosuppression by human herpesvirus 6A and 6B

Future Virology

Volumn 8, Issue 3, 2013, Pages 273-287

  Dagna, Lorenzo ^a   Pritchett, Joshua C ^b   Lusso, Paolo ^c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b The HHV 6 Foundation   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

antigen presenting cells; CD46; chemokines; cytokines; HHV 6A; HHV 6B; immunomodulation; immunosuppression; receptors; T cells

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD14 ANTIGEN; CD161 ANTIGEN; CUTANEOUS T CELL ATTRACTING CHEMOKINE; EOTAXIN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEMBRANE COFACTOR PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 9; VIRUS DNA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; COMPLEMENT ACTIVATION; CRYPTOCOCCUS NEOFORMANS; CYCLIC AMP RESPONSIVE ELEMENT; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTION SENSITIVITY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84874678413     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.7     Document Type: Review

References (117)

1. Dagna L, Lusso P. Virus-encoded chemokines, chemokine receptors and chemokine-binding proteins: new paradigms for future therapy. Future Virol. 2(4), 353-368 (2007).
2. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol. Today 21(9), 447-455 (2000).
3. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu. Rev. Immunol. 18, 861-926 (2000).
4. Adams MJ, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012). Arch. Virol. 157(7), 1411-1422 (2012).
5. Ablashi DV, Balachandran N, Josephs SF et al. Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates. Virology 184(2), 545-552 (1991).
6. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 99(7), 817-827 (1999).
7. Kikuta H, Nakane A, Lu H, Taguchi Y, Minagawa T, Matsumoto S. Interferon induction by human herpesvirus 6 in human mononuclear cells. J. Infect. Dis. 162(1), 35-38 (1990).
8. Grivel JC, Ito Y, Faga G et al. Suppression of CCR5-but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat. Med. 7(11), 1232-1235 (2001).
9. Arena A, Liberto MC, Iannello D, Capozza AB, Foca A. Altered cytokine production after human herpes virus type 6 infection. New Microbiol. 22(4), 293-300 (1999).
10. Flamand L, Stefanescu I, Menezes J. Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15. J. Clin. Invest. 97(6), 1373-1381 (1996).
11. Flamand L, Gosselin J, D'Addario M et al. Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J. Virol. 65(9), 5105-5110 (1991).
12. Lusso P, Markham PD, Tschachler E et al. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J. Exp. Med. 167(5), 1659-1670 (1988).
13. Takahashi K, Sonoda S, Higashi K et al. Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J. Virol. 63(7), 3161-3163 (1989).
14. Lopez C, Pellett P, Stewart J et al. Characteristics of human herpesvirus-6. J. Infect. Dis. 157(6), 1271-1273 (1988).
15. Salahuddin SZ, Ablashi DV, Markham PD et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234(4776), 596-601 (1986).
16. Ablashi DV, Lusso P, Hung CL et al. Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6). Int. J. Cancer 42(5), 787-791 (1988).
17. Bandobashi K, Daibata M, Kamioka M et al. Human herpesvirus 6 (HHV-6)-positive Burkitt's lymphoma: establishment of a novel cell line infected with HHV-6. Blood 90(3), 1200-1207 (1997).
18. Burd EM, Carrigan DR. Human herpesvirus 6 (HHV-6)-associated dysfunction of blood monocytes. Virus Res. 29(1), 79-90 (1993).
19. Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. Latent human herpesvirus 6 infection of human monocytes/macrophages. J. Gen. Virol. 72 (Pt 6), 1401-1408 (1991).
20. Smith A, Santoro F, Di Lullo G, Dagna L, Verani A, Lusso P. Selective suppression of IL-12 production by human herpesvirus 6. Blood 102(8), 2877-2884 (2003).
21. Arena A, Merendino RA, Bonina L, Iannello D, Stassi G, Mastroeni P. Role of IL-15 on monocytic resistance to human herpesvirus 6 infection. New Microbiol. 23(2), 105-112 (2000).
22. Kondo K, Kondo T, Shimada K, Amo K, Miyagawa H, Yamanishi K. Strong interaction between human herpesvirus 6 and peripheral blood monocytes/macrophages during acute infection. J. Med. Virol. 67(3), 364-369 (2002).
23. Luppi M, Barozzi P, Morris C et al. Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. J. Virol. 73(1), 754-759 (1999).
24. Isomura H, Yoshida M, Namba H, Yamada M. Interaction of human herpesvirus 6 with human CD34 positive cells. J. Med. Virol. 70(3), 444-450 (2003).
25. Isomura H, Yoshida M, Namba H et al. Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro. J. Gen. Virol. 81(Pt 3), 663-673 (2000).
26. Knox KK, Carrigan DR. In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. J. Infect. Dis. 165(5), 925-929 (1992).
27. Isomura H, Yamada M, Yoshida M et al. Suppressive effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells. J. Med. Virol. 52(4), 406-412 (1997).
28. Yasukawa M, Ohminami H, Sada E et al. Latent infection and reactivation of human herpesvirus 6 in two novel myeloid cell lines. Blood 93(3), 991-999 (1999).
29. Drobyski WR, Dunne WM, Burd EM et al. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. J. Infect. Dis. 167(3), 735-739 (1993).
30. Johnston RE, Geretti AM, Prentice HG et al. HHV-6-related secondary graft failure following allogeneic bone marrow transplantation. Br. J. Haematol. 105(4), 1041-1043 (1999).
31. Dulery R, Salleron J, Dewilde A et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol. Blood Marrow Transplant. 18(7), 1080-1089 (2012).
32. Pichereau C, Desseaux K, Janin A et al. The complex relationship between human herpesvirus 6 and acute graft-versus-host disease. Biol. Blood Marrow Transplant. 18(1), 141-144 (2012).
33. Zerr DM, Boeckh M, Delaney C et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18(11), 1700-1708 (2012).
34. Lusso P, Malnati M, De Maria A et al. Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J. Immunol. 147(2), 685-691 (1991).
35. Lusso P, Malnati MS, Garzino-Demo A, Crowley RW, Long EO, Gallo RC. Infection of natural killer cells by human herpesvirus 6. Nature 362(6419), 458-462 (1993).
36. Lusso P, Garzino-Demo A, Crowley RW, Malnati MS. Infection of gamma/delta T lymphocytes by human herpesvirus 6: transcriptional induction of CD4 and susceptibility to HIV infection. J. Exp. Med. 181(4), 1303-1310 (1995).
37. Li L, Gu B, Zhou F et al. Human herpesvirus 6A infects human embryonic fibroblasts and induces G2/M arrest and cell death. J. Med. Virol. 84(4), 657-663 (2012).
38. Gupta S, Agrawal S, Gollapudi S. Differential effect of human herpesvirus 6A on cell division and apoptosis among naive and central and effector memory CD4+ and CD8+ T-cell subsets. J. Virol. 83(11), 5442-5450 (2009).
39. Lusso P, De Maria A, Malnati M et al. Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature 349(6309), 533-535 (1991).
40. Grivel JC, Santoro F, Chen S et al. Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. J. Virol. 77(15), 8280-8289 (2003).
41. Takemoto M, Imasawa T, Yamanishi K, Mori Y. Role of dendritic cells infected with human herpesvirus 6 in virus transmission to CD4+ T cells. Virology 385(2), 294-302 (2009).
42. Yasukawa M, Inoue Y, Ohminami H, Terada K, Fujita S. Apoptosis of CD4+ T lymphocytes in human herpesvirus-6 infection. J. Gen. Virol. 79 (Pt 1), 143-147 (1998).
43. Oster B, Kaspersen MD, Kofod-Olsen E, Bundgaard B, Hollsberg P. Human herpesvirus 6B inhibits cell proliferation by a p53-independent pathway. J. Clin. Virol. 37(Suppl. 1), S63-68 (2006).
44. Oster B, Bundgaard B, Hollsberg P. Human herpesvirus 6B induces cell cycle arrest concomitant with p53 phosphorylation and accumulation in T cells. J. Virol. 79(3), 1961-1965 (2005).
45. Takemoto M, Mori Y, Ueda K, Kondo K, Yamanishi K. Productive human herpesvirus 6 infection causes aberrant accumulation of p53 and prevents apoptosis. J. Gen. Virol. 85(Pt 4), 869-879 (2004).
46. Li L, Gu B, Zhou F et al. Human herpesvirus 6 suppresses T cell proliferation through induction of cell cycle arrest in infected cells in the G2/M phase. J. Virol. 85(13), 6774-6783 (2011).
47. Chi J, Wang F, Li L et al. The role of MAPK in CD4+ T cells Toll-like receptor 9-mediated signaling following HHV-6 infection. Virology 422(1), 92-98 (2012).
48. Yeo WM, Isegawa Y, Chow VT. The U95 protein of human herpesvirus 6B interacts with human GRIM-19: silencing of U95 expression reduces viral load and abrogates loss of mitochondrial membrane potential. J. Virol. 82(2), 1011-1020 (2008).
49. Janelle ME, Flamand L. Phenotypic alterations and survival of monocytes following infection by human herpesvirus-6. Arch. Virol. 151(8), 1603-1614 (2006).
50. Ichimi R, Jin-No T, Ito M. Induction of apoptosis in cord blood lymphocytes by HHV-6. J. Med. Virol. 58(1), 63-68 (1999).
51. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9, 431-455 (1991).
52. Naniche D, Varior-Krishnan G, Cervoni F et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67(10), 6025-6032 (1993).
53. Greenstone HL, Santoro F, Lusso P, Berger EA. Human Herpesvirus 6 and measles virus employ distinct CD46 domains for receptor function. J. Bio. Chem. 277(42), 39112-39118 (2002).
54. Santoro F, Greenstone HL, Insinga A et al. Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46. J. Bio. Chem. 278(28), 25964-25969 (2003).
55. Mori Y, Akkapaiboon P, Yang X, Yamanishi K. The human herpesvirus 6 U100 gene product is the third component of the gH-gL glycoprotein complex on the viral envelope. J. Virol. 77(4), 2452-2458 (2003).
56. Smith AP, Paolucci C, Di Lullo G, Burastero SE, Santoro F, Lusso P. Viral replication-independent blockade of dendritic cell maturation and interleukin-12 production by human herpesvirus 6. J. Virol. 79(5), 2807-2813 (2005).
57. Niiya H, Lei J, Guo Y et al. Human herpesvirus 6 impairs differentiation of monocytes to dendritic cells. Exp. Hematol. 34(5), 642-653 (2006).
58. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421(6921), 388-392 (2003).
59. Wang F, Yao K, Yin QZ et al. Human herpesvirus-6-specific interleukin 10-producing CD4+ T cells suppress the CD4+ T-cell response in infected individuals. Microbiol. Immunol. 50(10), 787-803 (2006).
60. Mori Y, Seya T, Huang HL, Akkapaiboon P, Dhepakson P, Yamanishi K. Human herpesvirus 6 variant A but not variant B induces fusion from without in a variety of human cells through a human herpesvirus 6 entry receptor, CD46. J. Virol. 76(13), 6750-6761 (2002).
61. Schnorr JJ, Dunster LM, Nanan R, Schneider-Schaulies J, Schneider-Schaulies S, Ter Meulen V. Measles virus-induced down-regulation of CD46 is associated with enhanced sensitivity to complement-mediated lysis of infected cells. Eur. J. Immunol. 25(4), 976-984 (1995).
62. Niiya H, Azuma T, Jin L et al. Transcriptional downregulation of DC-SIGN in human herpesvirus 6-infected dendritic cells. J. Gen. Virol. 85(Pt 9), 2639-2642 (2004).
63. Hasegawa H, Utsunomiya Y, Yasukawa M, Yanagisawa K, Fujita S. Induction of G protein-coupled peptide receptor EBI 1 by human herpesvirus 6 and 7 infection in CD4+ T cells. J. Virol. 68(8), 5326-5329 (1994).
64. Hirata Y, Kondo K, Yamanishi K. Human herpesvirus 6 downregulates major histocompatibility complex class I in dendritic cells. J. Med. Virol. 65(3), 576-583 (2001).
65. Glosson NL, Hudson AW. Human herpesvirus-6A and -6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 365(1), 125-135 (2007).
66. Sullivan BM, Coscoy L. Downregulation of the T-cell receptor complex and impairment of T-cell activation by human herpesvirus 6 u24 protein. J. Virol. 82(2), 602-608 (2008).
67. Flamand L, Romerio F, Reitz MS, Gallo RC. CD4 promoter transactivation by human herpesvirus 6. J. Virology 72(11), 8797-8805 (1998).
68. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 85(5), 1263-1271 (1995).
69. Inagi R, Guntapong R, Nakao M et al. Human herpesvirus 6 induces IL-8 gene expression in human hepatoma cell line, Hep G2. J. Med. Virol. 49(1), 34-40 (1996).
70. Mayne M, Cheadle C, Soldan SS et al. Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms. J. Virol. 75(23), 11641-11650 (2001).
71. Chi J, Gu B, Zhang C et al. Human herpesvirus 6 latent infection in patients with glioma. J. Infect. Dis. 206(9), 1394-1398 (2012).
72. Nastke MD, Becerra A, Yin L et al. Human CD4+ T cell response to human herpesvirus 6. J. Virol. 86(9), 4776-4792 (2012).
73. Yao K, Graham J, Akahata Y, Oh U, Jacobson S. Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding. J. Neuroimmune Pharmacol. 5(3), 469-478 (2010).
74. Caruso A, Favilli F, Rotola A et al. Human herpesvirus-6 modulates RANTES production in primary human endothelial cell cultures. J. Med. Virol. 70(3), 451-458 (2003).
75. Jaworska J, Gravel A, Fink K, Grandvaux N, Flamand L. Inhibition of transcription of the beta interferon gene by the human herpesvirus 6 immediate-early 1 protein. J. Virol. 81(11), 5737-5748 (2007).
76. Kawabe S, Ito Y, Ohta R et al. Comparison of the levels of human herpesvirus 6 (HHV-6) DNA and cytokines in the cerebrospinal fluid and serum of children with HHV-6 encephalopathy. J. Med. Virol. 82(8), 1410-1415 (2010).
77. Martin LK, Schub A, Dillinger S, Moosmann A. Specific CD8+ T cells recognize human herpesvirus 6B. Eur. J. Immunol. 42(11), 2901-2912 (2012).
78. Yoshikawa T, Kato Y, Ihira M et al. Kinetics of cytokine and chemokine responses in patients with primary human herpesvirus 6 infection. J. Clin. Virol. 50(1), 65-68 (2011).
79. Milne RS, Mattick C, Nicholson L, Devaraj P, Alcami A, Gompels UA. RANTES binding and down-regulation by a novel human herpesvirus-6 beta chemokine receptor. J. Immunol. 164(5), 2396-2404 (2000).
80. French C, Menegazzi P, Nicholson L, Macaulay H, Diluca D, Gompels UA. Novel, nonconsensus cellular splicing regulates expression of a gene encoding a chemokine-like protein that shows high variation and is specific for human herpesvirus 6. Virology 262(1), 139-151 (1999).
81. Isegawa Y, Ping Z, Nakano K, Sugimoto N, Yamanishi K. Human herpesvirus 6 open reading frame U12 encodes a functional beta-chemokine receptor. J. Virol. 72(7), 6104-6112 (1998).
82. Zou P, Isegawa Y, Nakano K, Haque M, Horiguchi Y, Yamanishi K. Human herpesvirus 6 open reading frame U83 encodes a functional chemokine. J. Virol. 73(7), 5926-5933 (1999).
83. Catusse J, Spinks J, Mattick C et al. Immunomodulation by herpesvirus U51A chemokine receptor via CCL5 and FOG-2 down-regulation plus XCR1 and CCR7 mimicry in human leukocytes. Eur. J. Immunol. 38(3), 763-777 (2008).
84. Fitzsimons CP, Gompels UA, Verzijl D et al. Chemokine-directed trafficking of receptor stimulus to different g proteins: selective inducible and constitutive signaling by human herpesvirus 6-encoded chemokine receptor U51. Mol. Pharmacol. 69(3), 888-898 (2006).
85. Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S. The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro. J. Virol. 79(18), 11914-11924 (2005).
86. Luttichau HR, Clark-Lewis I, Jensen PO, Moser C, Gerstoft J, Schwartz TW. A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6. J. Biol. Chem. 278(13), 10928-10933 (2003).
87. Catusse J, Parry CM, Dewin DR, Gompels UA. Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leukocyte chemotaxis and receptor internalization. Blood 109(9), 3633-3639 (2007).
88. Dewin DR, Catusse J, Gompels UA. Identification and characterization of U83A viral chemokine, a broad and potent beta-chemokine agonist for human CCRs with unique selectivity and inhibition by spliced isoform. J. Immunol. 176(1), 544-556 (2006).
89. Yagasaki H, Kato M, Shimizu N, Shichino H, Chin M, Mugishima H. Autoimmune hemolytic anemia and autoimmune neutropenia in a child with erythroblastopenia of childhood (TEC) caused by human herpesvirus-6 (HHV-6). Ann. Hematol. 90(7), 851-852 (2011).
90. Grima P, Chiavaroli R, Calabrese P, Tundo P, Grima P. Severe hepatitis with autoimmune features following a HHV-6: a case report. Cases J. 1(1), 110 (2008).
91. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann. Neurol. 53(2), 189-197 (2003).
92. Broccolo F, Drago F, Paolino S et al. Reactivation of human herpesvirus 6 (HHV 6) infection in patients with connective tissue diseases. J. Clin. Virol. 46(1), 43-46 (2009).
93. Caselli E, Zatelli MC, Rizzo R et al. Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis. PLoS Pathog. 8(10), e1002951 (2012).
94. Krueger GR, Sander C, Hoffmann A, Barth A, Koch B, Braun M. Isolation of human herpesvirus-6 (HHV-6) from patients with collagen vascular diseases. In Vivo 5(3), 217-225 (1991).
95. Lusso P. HHV-6 and the immune system: mechanisms of immunomodulation and viral escape. J. Clin. Virol. 37(Suppl. 1), S4-10 (2006).
96. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Bartolome M, Arroyo R. Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients. J. Clin. Virol. 37(Suppl. 1), S24-S26 (2006).
97. Virtanen JO, Zabriskie JB, Siren V et al. Co localization of human herpes virus 6 and tissue plasminogen activator in multiple sclerosis brain tissue. Med. Sci. Monit. 11(3), BR84-BR87 (2005).
98. Friedman JE, Lyons MJ, Cu G et al. The association of the human herpesvirus-6 and MS. Mult. Scler. 5(5), 355-362 (1999).
99. Challoner PB, Smith KT, Parker JD et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl Acad. Sci. USA 92(16), 7440-7444 (1995).
100. Akhyani N, Berti R, Brennan MB et al. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J. Infect. Dis. 182(5), 1321-1325 (2000).
101. Alvarez-Lafuente R, De Las Heras V, Bartolome M, Picazo JJ, Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch. Neurol. 61(10), 1523-1527 (2004).
102. Rotola A, Merlotti I, Caniatti L et al. Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. Mult. Scler. 10(4), 348-354 (2004).
103. Ablashi DV, Eastman HB, Owen CB et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J. Clin. Virol. 16(3), 179-191 (2000).
104. Sola P, Merelli E, Marasca R et al. Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction. J. Neurol. Neurosurg. Psychiatry 56(8), 917-919 (1993).
105. Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR. Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report. Mult. Scler. 4(6), 490-496 (1998).
106. Soldan SS, Berti R, Salem N et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. 3(12), 1394-1397 (1997).
107. Caselli E, Boni M, Bracci A et al. Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis. J. Clin. Microbiol. 40(11), 4131-4137 (2002).
108. Ben-Fredj N, Ben-Selma W, Rotola A et al. Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients. J. Neurovirol. 19(1), 42-47 (2013).
109. Simpson S, Jr., Taylor B, Dwyer DE et al. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult. Scler. 18(6), 799-806 (2012).
110. Cirone M, Cuomo L, Zompetta C et al. Human herpesvirus 6 and multiple sclerosis: a study of T cell cross-reactivity to viral and myelin basic protein antigens. J. Med. Virol. 68(2), 268-272 (2002).
111. Garcia-Montojo M, Martinez A, De Las Heras V et al. Herpesvirus active replication in multiple sclerosis: a genetic control? J. Neurol. Sci. 311(1-2), 98-102 (2011).
112. Dominguez-Mozo MI, Garcia-Montojo M, De Las Heras V et al. MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. BMC Neurol. 12(1), 107 (2012).
113. Soldan SS, Fogdell-Hahn A, Brennan MB et al. Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann. Neurol. 50(4), 486-493 (2001).
114. Astier AL, Hafler DA. Abnormal Tr1 differentiation in multiple sclerosis. J. Neuroimmunol. 191(1-2), 70-78 (2007).
115. Alvarez-Lafuente R, Blanco-Kelly F, Garcia-Montojo M et al. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Mult. Scler. 17(5), 513-520 (2011).
116. Fogdell-Hahn A, Soldan SS, Shue S et al. Co-purification of soluble membrane cofactor protein (CD46) and human herpesvirus 6 variant A genome in serum from multiple sclerosis patients. Virus Res. 110(1-2), 57-63 (2005).
117. Cermelli C, Cenacchi V, Beretti F, Pezzini F, Luca DD, Blasi E. Human herpesvirus-6 dysregulates monocyte-mediated anticryptococcal defences. J. Med. Microbial. 55(Pt 6), 695-702 (2006).